MUMBAI, India , Nov. 26, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd . (NSE: PPLPHARMA) (BSE: 543635), today announced the successful completion of its journey to compliance with global requirements for nitrosamine impurities in pharmaceuticals.

Nitrosamines are unintended carcinogenic byproducts that can be found in certain medications. International guidelines on nitrosamine drug substance-related impurities (NDSRIs) have evolved significantly over the last few years, requiring pharmaceutical companies to adapt their operations to maintain compliance. In response, Piramal Pharma Solutions has implemented a robust, multi-step action plan to ensure regulatory alignment with the la

See Full Page